USPTO serial 99204288
GLOBIN SWITCHING
Reviewed by CopyMark Law Group
Status 760
- Filing date
- Status date
- Registration date
- —
- Examiner
- LUEKEN, ABIGAIL JOSEPHINE
- Law office
- TMEG LAW OFFICE 109
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with GLOBIN SWITCHING?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Somerville, MA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
CHRISTINA M. LICURSI
Christina M. Licursi Wolf, Greenfield & Sacks, P.C.600 Atlantic AvenueBoston, MA 02210-2206United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical, therapeutic and biopharmaceutical preparations and agents for the treatment of cancer, autoimmune disorders, transplant rejections, inflammatory disease, immunological disorders, metabolic disorders, neurological disorders, genetic disorders, psychiatric disorders, gastroenterological disorders, renal disorders, cardiovascular disorders, dermatological disorders, respiratory disorders | ACTIVE | — |
| 042 | Research and development of new products in the nature of pharmaceutical, therapeutic and biopharmaceutical preparations and agents; research and development of technology in the field of medicine and diagnostic testing featuring pharmaceutical, therapeutic and biopharmaceutical preparations and agents; pharmaceutical drug development and research; scientific research in the field of drug discovery and development; biomedical research services; pharmaceutical drug development services, namely, preclinical development of therapeutic products; bioinformatic services in the nature of scientific research, namely, collecting and analyzing complex biological data through the use of artificial intelligence; providing temporary use of non-downloadable artificial intelligence (AI) computer software for molecular design in the fields of pharmaceutical research, medicine, and diagnostic testing for disease; scientific diagnostic and screening services for scientific research purposes, namely, conducting scientific diagnostic testing and evaluation of molecules developed through artificial intelligence means for the combating of diseases; scientific research, namely, research and analysis services in the fields of artificial intelligence and machine learning analytics and research relating to drug development; providing on-line non-downloadable artificial intelligence (AI) software for the capture, collection, conversion, analysis, transmission, processing, receiving, recording, storage and transmission of data, images, information in the fields of healthcare, biomedical and genomic research; providing on-line non-downloadable artificial intelligence (AI) software featuring machine learning for data analysis in the fields of healthcare, biomedical and genomic research; providing on-line non-downloadable artificial intelligence (AI) software featuring machine learning for drug analysis in drug discovery and development; scientific research, namely, research and analysis services in the scientific fields of artificial intelligence and machine learning analytics, healthcare, biomedical and genomic research; providing on-line non-downloadable artificial intelligence (AI) software featuring machine learning for collecting, analyzing, assessing, interpreting and predicting medical, health, transcriptional, genetic, genomic, pharmacogenomic, nutrigenomic, microbiomic, metabolomic, proteomic, biochemistry, and biomarker information, associations, conditions, outcomes, effects and risks in the field of scientific research; medical research services, namely, conducting diagnostic testing and evaluation of molecules developed through artificial intelligence means for the combating of diseases | ACTIVE | — |
| 044 | Medical diagnostic and screening services in the fields of medicine, diagnostic testing, molecular evaluation, and combating of diseases utilizing artificial intelligence and molecular research | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 5, 2026 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Nov 5, 2026 | EXPI | EX PARTE APPEAL-INSTITUTED | — |
| Nov 5, 2026 | JURT | JURISDICTION RESTORED TO EXAMINING ATTORNEY | — |
| Nov 5, 2026 | EXAF | EXPARTE APPEAL RECEIVED AT TTAB | — |
| Nov 2, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 30, 2026 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Jul 30, 2026 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| May 5, 2026 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| May 5, 2026 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| May 5, 2026 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Apr 14, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 14, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 14, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 6, 2026 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Jan 6, 2026 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Oct 15, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 15, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 15, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 15, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 3, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 27, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| May 27, 2025 | NWAP | NEW APPLICATION ENTERED | — |